TIMH
CRSP icon

Tilt Investment Management Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Tilt Investment Management Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,750
Closed -$443K – 125
2023
Q3 		$443K Hold
9,750
– – 0.32% 95
2023
Q2 		$547K Buy
9,750
+3,400
+54% +$193K 0.36% 82
2023
Q1 		$282K Hold
6,350
– – 0.21% 115
2022
Q4 		$258K Buy
+6,350
New +$337K 0.22% 116

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Tilt Investment Management Holdings's CRSP Position: Q4 2023 in Review

Tilt Investment Management Holdings sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 9,750 shares — an estimated $443K sold.

Tilt Investment Management Holdings first reported a position in CRSP in Q4 2022 and held it in 4 quarters. The position peaked at $547K in Q2 2023. 470 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Tilt Investment Management Holdings reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Tilt Investment Management Holdings sold 9,750 CRISPR Therapeutics shares in Q4 2023, an estimated $443K.
  • Tilt Investment Management Holdings first reported a position in CRISPR Therapeutics in Q4 2022 and held it in 4 quarters.
  • Tilt Investment Management Holdings's CRISPR Therapeutics position peaked at $547K in Q2 2023.
  • 470 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Tilt Investment Management Holdings's 13F filing for Q4 2023, filed 31 Jan 2024.